Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Talk with MIC about Local Tax Grants to Deal with Increased Costs of Flu Vaccines: Health Service Bureau Chief
October 28, 2015
- 6 Drugs Get Sakigake Designation for Fast-Track Review
October 27, 2015
- New Chief of MHLW Health Policy Bureau Vows to Balance Generic Push and Innovation
October 27, 2015
- ICH Revamped as Legal Entity, PMDA’s Tominaga Picked as Vice Assembly Chair
October 27, 2015
- MHLW to Implement Steps to Curb Social Security Spending as Needed: New Top Bureaucrat
October 26, 2015
- MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
- MHLW Lifts Request for Kaketsuken to Suspend Flu Vaccine Shipment
October 23, 2015
- Chuikyo OKs Expansion of Health Coverage for Investigator-Led Trials
October 22, 2015
- Impact of Z2 Rule to Be Discussed toward FY2016 Reform: MHLW
October 22, 2015
- New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
- MHLW Likely to Announce 5 or So Sakigake Products Next Week
October 22, 2015
- Add Interstitial Pneumonia to Daklinza, Sunvepra Labels: MHLW
October 21, 2015
- MHLW to Show Detailed Steps to Foster Pharma Sector in November
October 21, 2015
- Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
- 5 Members to Leave Chuikyo before Full-Fledged Debate Begins for 2016 Reform
October 20, 2015
- Govt to Reduce Stockpiles of Anti-Pandemic Flu Drugs
October 19, 2015
- PAFSC 1st Committee to Discuss Lexapro for Social Anxiety Disorder on Oct. 30
October 19, 2015
- AMED to Launch Project to Fund Orphan Drug Hopefuls
October 19, 2015
- AMED’s Joint Drug Discovery Project to See Match-Ups by the End of October: President Suematsu
October 16, 2015
- Chuikyo Subcommittee OKs 70% Threshold for DPC Incentive
October 16, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…